A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
28
Participants
Timeline
Start Date
Not specified
Conditions
HIV Infections
Interventions
BIOLOGICAL
HIV-1 Peptide Immunogen, Multivalent
Trial Locations (1)
21205
Johns Hopkins Univ / Ctr for Immunological Research, Baltimore
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000795 - A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects | Biotech Hunter | Biotech Hunter